首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1727692

基因的共同研究及授權契約:2018年～2025年

Genomic Collaboration and Licensing Deals 2018-2025

出版日期: 2025年05月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

"基因組合作與授權協議" 提供了前所未有的途徑，讓我們能夠全面了解世界領先生物製藥公司達成的基因組協議。

本報告經過全面修訂和更新，提供了 2018 年至 2025 年基因組交易的詳細資訊。它詳細了解並分析了公司達成基因組交易的方式和原因。這些交易通常涉及多個環節，從合作研發開始，到成果商業化結束。

本報告涵蓋合作、開發、研究和授權交易。

本報告包含自 2018 年以來宣布的 639 項基因組交易的完整列表，包括財務條款（如有），以及交易方披露的實際基因組合作交易的在線交易記錄鏈接。此外，報告還收錄了公司及其合作夥伴向美國證券交易委員會提交的合約文件（如有）。

本報告第一章介紹了基因組學交易。

第一章是對報告的介紹。

第二章概述了自2018年以來的基因組學交易趨勢。

第三章概述了自2018年以來的主要基因組學交易。交易按交易金額排序。

第四章列出了在基因組學交易中最活躍的25家公司，並附有簡要摘要，隨後是基因組學交易的完整列表以及公開的合約文件。

第五章對自2018年1月以來簽署和宣布的基因組學交易進行了全面深入的回顧，合約文件已公開發布。

第六章全面深入地回顧了自2018年1月以來簽署和宣布的基因組學合作交易。本章按感興趣的特定基因組學技術類型進行組織。

報告還包含大量圖表，展示了自2018年以來基因組學交易的趨勢和活動。

此外，綜合交易目錄按公司A-Z、交易類型和治療目標進行組織。每個交易標題都透過網頁連結連結到線上交易記錄，並包含合約文件（如有），方便您隨時存取每份交易文件。

主要優勢

基因體學合作與授權交易提供讀者以下主要優勢：

了解 2018 年及以後的交易趨勢
瀏覽基因體學合作與授權交易
基準分析 - 確定交易的市場價值
財務條款 - 一次性付款、里程碑付款、特許權使用費
按公司 A-Z、交易類型和治療領域分類的交易目錄
主要交易價值
最活躍的交易撮合者
確定每筆交易的資產和交易條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款是否適合您的合作公司
節省數百小時的研究時間

研究範圍

基因組學合作與許可交易 "許可協議" 旨在深入了解基因組學趨勢以及世界領先生物製藥公司達成的交易結構。

基因體學合作與授權協議包括：

生物製藥產業的基因組學交易趨勢
涵蓋製藥和生物技術的基因組學交易記錄目錄
按價值排序的主要基因組學交易
最活躍的基因組學許可交易撮合者
"基因組學合作與許可協議" 提供全面的交易記錄存取權限，包括合約文件（如有）。

分析合約文件有助於進行盡職調查：

授予或選擇的具體權利是什麼？
合約實際上授予了合作公司哪些權利？
授予了哪些獨家權利？
合約的付款結構是怎樣的？
如何審計銷售和付款？
合約期限是多久？
合約的關鍵條款是如何定義的？
如何處理並擁有知識產權？
誰負責商業化？
誰負責開發、供應和製造？
如何管理保密和資訊揭露？
如何解決爭議？
合約在什麼情況下可以終止？
如果所有權發生變更會怎樣？
雙方約定了哪些分授權和分包條款？
公司堅持哪些標準條款？
哪些標準條款似乎因合作夥伴和交易類型的不同而有所差異？
公司在契約法方面主張哪些管轄權？

This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.

Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2018
Browse genomic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

Trends in genomic dealmaking in the biopharma industry
Directory of genomic deal records covering pharmaceutical and biotechnology
The leading genomic deals by value
Most active genomic licensing dealmakers
Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomic dealmaking

2.1. Introduction
2.2. Genomic deals over the years
2.3. Most active genomic dealmakers
2.4. Genomic deals by deal type
2.5. Genomic deals by therapy area
2.6. Genomic deals by industry sector
2.7. Deal terms for genomic deals
- 2.7.1 Genomic deals headline values
- 2.7.2 Genomic deal upfront payments
- 2.7.3 Genomic deal milestone payments
- 2.7.4 Genomic royalty rates